Could a cancer drug ease long COVID? new trial aims to find out
NCT ID NCT06766825
First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 3 times
Summary
This Phase 2 trial tests whether the drug plitidepsin can improve overall health in 90 adults with moderate-to-severe long COVID symptoms. Participants receive either plitidepsin or a placebo intravenously over four 3-day cycles, with a 90-day follow-up. The study is double-blind and randomized to see if the drug safely reduces symptom burden.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- plitidepsin
- What this could lead to
- If it works, this could point toward a treatment that eases long COVID symptoms and improves daily function.
- What could go wrong
- This is a small, early-phase trial (90 people) testing a drug that may not work better than placebo. Side effects from the drug and pre-medications are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Could exercise retrain the heart in long COVID?
- Can brain games and gentle currents lift long COVID brain fog?
- Brain fog after COVID: can a mental workout restore focus?
- Can brain training zap long COVID brain fog?
- Micro-Choices, macro impact? a novel behavioral approach takes on fatigue